IBIO News and Press, iBio Inc. From 10/21/25

2025-10-21 09:45:45 ET DENVER, Colo., Oct 21, 2025 ( 247marketnews.com )- Markets opened Tuesday with a biotech-heavy tailwind, as investor sentiment surged on a wave of transformational clinical updates, strategic partnerships, and promising regulatory progress across the healthcare an...

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 Novem...

2025-10-17 06:53:05 ET Roanna Ruiz from Leerink Partners issued a price target of $2.00 for IBIO on 2025-10-17 10:19:36. The adjusted price target was set to $2.00. At the time of the announcement, IBIO was trading at $0.8455. The overall price target consensus is at $3....

2025-09-18 18:43:56 ET iBio, Inc. (IBIO) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.77%. The average open to low on the day of earnings was -5.06%. The average open to close on th...

2025-09-18 18:38:57 ET iBio, Inc. (IBIO) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in IBIO stock price following earnings has averaged ±1.28% , with a median of 1.21%. The singl...

2025-09-05 07:47:21 ET More on iBio iBio prices $50M public offering iBio drops on proposed public offering Seeking Alpha’s Quant Rating on iBio Historical earnings data for iBio Financial information for iBio Read the full article on...

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. “This fiscal year has been...

Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Cap...

2025-06-24 15:00:54 ET iBio, Inc. ( IBIO ) is pushing deeper into the obesity treatment race with its partner AstralBio, unveiling compelling preclinical data for a new antibody-based therapy that targets the amylin receptor . This program focuses on a novel approach to help reg...

2025-06-24 14:00:35 ET Capricor Therapeutics Rises 18% on FDA Progress for Duchenne Cell Therapy Capricor Therapeutics, Inc. ( CAPR ) jumped 18.23% to lead the PRISM Emerging Biotech Index after providing a regulatory update on its Biologics License Application (BLA) for...